Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma By Ogkologos - July 8, 2025 474 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MIDAS study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Grace and Love for Full Hands March 31, 2021 Navigating the Challenges of Gynecologic Cancer Survivorship: An Expert Perspective May 10, 2022 What Is Scanxiety? How People With Cancer and Survivors Can Cope October 28, 2021 9 Ways to Use Social Media for Support Throughout Your Cancer... February 4, 2021 Load more HOT NEWS A Combination of Trifluridine-Tipiracil Plus Bevacizumab Results in Longer Overall Survival... Six Months Immunogenicity of COVID-19 mRNA-based Vaccine in Patients with Actively... What People With Breast Cancer and Survivors Should Know About Exercising... Age: the forgotten cancer risk factor?
